Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.71 +2.34 (+2.88%)
Official Closing Price Updated: 4:10 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Options: An Unlikely Source Of Income
Calls give the buyer the right, but not the obligation, to buy a stock at a specific price by a specific date. The seller of the call must deliver the stock if the buyer requests it. 
Via Talk Markets
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
There's no reason to succumb to gloom and doom here. 
Via The Motley Fool
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
From Merck & Co., Inc.
Via Business Wire
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Analysis: Merck &amp; Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
From Merck & Co., Inc.
Via Business Wire
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... 
Via Talk Markets
MarketBeat Week in Review – 8/19 - 8/23
Stocks closed the week higher on the near certainty that the Fed will cut interest rates in September, but in the short term, all eyes are on NVDA earnings 
Via MarketBeat
Topics Economy
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and... 
Via Benzinga
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Merck's rVSV-ZEBOV vaccine, the only WHO-prequalified vaccine for Ebola outbreaks caused by the Zaire ebolavirus, is FDA-approved for adults and children. A study on the 2018–20 Congo outbreak shows... 
Via Benzinga
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY. 
Via Talk Markets
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
Via MarketBeat
Topics Intellectual Property
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
This list of top-selling drugs could look drastically different in a few years. 
Via The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
Despite a possible recession, these two Dow Jones stocks are still a buy. 
Via The Motley Fool
Topics Economy Stocks
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth. 
Via InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and... 
Via Benzinga
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood's selling. He remains committed to Palo Alto Networks (PANW). He suggests... 
Via Benzinga
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased... 
Via Benzinga
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.